Early and longer-lasting treatment reduces risk of substance use disorder most significantly.
- Children can become seriously ill with a hyperinflammatory condition weeks after contracting COVID-19.
- SARS-CoV-2 virus can remain in the gut weeks after initial COVID-19 infection and move into the bloodstream.
- A drug developed to reverse intestinal permeability in celiac disease reduced MIS-C symptoms in a small number of children.
Lael Yonker, MD
Our results demonstrate the urgent need for the development of diagnostic and prognostic tools to advance our understanding and treatment of this devastating disease.
Pediatric pulmonologist, Massachusetts General Hospital
BOSTON — Scientists at Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH) have identified a promising drug candidate for the treatment of multi-inflammatory syndrome in children (MIS-C), they report in Clinical Care Explorations. MIS-C is a rare but severe and potentially life-threatening condition that usually develops in children weeks to months after they have experienced a mild or even asymptomatic case of COVID-19.
MIS-C occurs mainly in children and leads to high fevers and a hyperinflammatory response that can affect multiple organs, including the heart, brain and gastrointestinal organs. Symptoms include stomach pain, diarrhea, vomiting, dizziness and rash. Fifty-five of the 6,431 children diagnosed with MIS-C have died since May 2020, according to the Centers for Disease Control and Prevention.
A previous study by researchers from MGH and BWH showed that in cases of MIS-C, the SARS-CoV-2 virus, which causes COVID-19, can remain in the gut for weeks to months after the infection. When SARS-CoV-2 is present in the gut, an impaired mucosal barrier can allow small viral particles, such as the spike protein, to enter the bloodstream, leading to infections such as COVID-19 and in rare cases, the hyperinflammatory response that triggers MIS-C.
“Working collaboratively, we’ve been able to demonstrate that viral particles that remain in the gut long after COVID-19 infection can instigate MIS-C,” says co-senior author David Walt, PhD, principal investigator of the Walt Laboratory in the Brigham’s Department of Pathology. “Building on this important discovery, we wanted to see if treatment with a drug developed for another condition — celiac disease — could help resolve symptoms in children experiencing MIS-C.”
Based on these findings, the team administered the drug larazotide acetate to four extremely ill children ages 3 to 17 being treated for MIS-C at MGH. Larazotide decreases the release of zonulin, a molecule that can lead to increased gut permeability and an impaired mucosal barrier. The researchers compared the clinical outcomes of the four children who received larazotide plus steroids and intravenous immune globulin (IVIG) to 22 children who received only steroids and IVIG.
The children who received four daily oral doses of larazotide acetate had a significantly faster resolution of gastrointestinal symptoms and a slightly shorter hospital stay. Serum levels of the highly inflammatory spike protein associated with the SARS-CoV-2 virus dropped much more quickly in children treated with larazotide, clearing from the blood within one day, versus 10 days for children not treated with larazotide.
“These findings suggest that larazotide may provide a safe and beneficial adjuvant therapy for the treatment of MIS-C,” state the authors in the new paper. Adds lead author Lael Yonker, MD, pediatric pulmonologist and director of the Cystic Fibrosis Center at MassGeneral Hospital for Children (MGHfC): “Our results demonstrate the urgent need for the development of diagnostic and prognostic tools to advance our understanding and treatment of this devastating disease.”
Yonker, with the support of Alessio Fasano, MD, director of the Mucosal Immunology and Biology Research Center and chief of the Division of Pediatric Gastroenterology and Nutrition at MGHfC, first applied to the FDA for emergency compassionate use of larazotide in the treatment of MIS-C in February 2021. With the approval of parents, the clinicians successfully administered larazotide to several severely ill children who were not responding to the prescribed therapies. Yonker and Fasano, along with colleagues from MGH, the Walt Laboratory at BWH and other institutions, published their results in July 2021 about earlier clinical successes with larazotide.
An expert in celiac disease and autoimmune disorders, Fasano developed larazotide acetate in the early 2000s as an adjunctive treatment for celiac disease. Larazotide is currently in Phase 3 human clinical trials for this purpose. Given its outstanding safety profile and early success in treating gastrointestinal complications of MIS-C, Yonker and Fasano initiated a clinical “proof of concept” randomized, double-blind, placebo-controlled study in August 2021 to evaluate the efficacy of larazotide acetate for children hospitalized with MIS-C at MGH.
The latest research is the cumulative result of “a strong team effort,” notes Fasano. “We connected the dots to capitalize on the ongoing research related to the activation of the zonulin pathway in a variety of inflammatory conditions.” Recent research includes findings that demonstrate how closely MIS-C resembles Kawasaki disease, another inflammatory condition in children.
“Kawasaki disease is caused by a zonulin-dependent mechanism that has a similar effect upon important organs, including the heart and gastrointestinal system,” says Fasano. “This led us to the conclusion that a similar mechanism can also be at play in MIS-C. It was only logical to propose the compassionate use of larazotide in kids affected by MIS-C,” he says, adding that clinical results with a small number of children have been “so promising that the FDA gave us the green light last August to start a clinical trial in children admitted to MGH who are affected by MIS-C.”
“What makes our approach unique is that we have been able to identify the zonulin-dependent leak of the spike protein from the gut lumen into the circulatory system. This provides us not only with a diagnostic tool by searching for the spike protein in blood but also with a therapeutic target of blocking zonulin-dependent increased gut permeability to treat this serious complication of COVID-19 infection,” says Fasano.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of “America’s Best Hospitals.”
About Brigham and Women’s Hospital
Brigham and Women’s Hospital, a global leader in creating a healthier world, is a founding member of Mass General Brigham and a teaching affiliate of Harvard Medical School. With more than 1,000 inpatient beds, approximately 60,000 inpatient stays, and 1.7 million outpatient encounters annually, the Brigham’s 2,200 physicians provide expert care in virtually every medical and surgical specialty to patients locally, regionally, and around the world. An international leader in basic, clinical, and translational research, Brigham and Women’s Hospital has nearly 5,000 scientists, including physician-investigators, renowned biomedical researchers and faculty supported by nearly $750 million in funding. The Brigham’s medical preeminence dates back to 1832, and now, with over 20,000 employees, that rich history is the foundation for its commitment to patient care, research, innovation, and community.
Related News and Articles
- Press Release
- May | 16 | 2022
Preventing medication administration errors and improving efficiency during surgery enhances patient care.
- Press Release
- Apr | 18 | 2022
The condition is driven not by “plumbing” defects but rather by problems with brain stem cells.
- Press Release
- Apr | 14 | 2022
ACTIVATE trial generated positive safety and efficacy data for mitapivat.
- Press Release
- Apr | 11 | 2022
Important new clues about the genetic basis of schizophrenia have emerged in a landmark study led by investigators at the Analytic and Translational Genetics Unit (ATGU) at MGH and the Broad Institute of MIT and Harvard.
- Press Release
- Apr | 6 | 2022
Women see gains in representation, but minority groups remain underrepresented.